CL2008000606A1 - Composicion analgesica en forma de dosificacion parenteral unitaria o en una forma de dosificacion unitaria adecuada para una administracion por la mucosa o la dermis que comprende buprenorfina y naloxona, util para el tratamiento del dolor. - Google Patents

Composicion analgesica en forma de dosificacion parenteral unitaria o en una forma de dosificacion unitaria adecuada para una administracion por la mucosa o la dermis que comprende buprenorfina y naloxona, util para el tratamiento del dolor.

Info

Publication number
CL2008000606A1
CL2008000606A1 CL200800606A CL2008000606A CL2008000606A1 CL 2008000606 A1 CL2008000606 A1 CL 2008000606A1 CL 200800606 A CL200800606 A CL 200800606A CL 2008000606 A CL2008000606 A CL 2008000606A CL 2008000606 A1 CL2008000606 A1 CL 2008000606A1
Authority
CL
Chile
Prior art keywords
buprenorfine
naloxone
dermis
mucosa
pain
Prior art date
Application number
CL200800606A
Other languages
English (en)
Spanish (es)
Inventor
Christopher Bourne Hyd Chapleo
Original Assignee
Reckitt Enckiser Healthcare Uk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reckitt Enckiser Healthcare Uk filed Critical Reckitt Enckiser Healthcare Uk
Publication of CL2008000606A1 publication Critical patent/CL2008000606A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CL200800606A 2007-03-01 2008-02-28 Composicion analgesica en forma de dosificacion parenteral unitaria o en una forma de dosificacion unitaria adecuada para una administracion por la mucosa o la dermis que comprende buprenorfina y naloxona, util para el tratamiento del dolor. CL2008000606A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0703968A GB2447016A (en) 2007-03-01 2007-03-01 Buprenorphine/naloxone compositions

Publications (1)

Publication Number Publication Date
CL2008000606A1 true CL2008000606A1 (es) 2008-10-03

Family

ID=37965735

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200800606A CL2008000606A1 (es) 2007-03-01 2008-02-28 Composicion analgesica en forma de dosificacion parenteral unitaria o en una forma de dosificacion unitaria adecuada para una administracion por la mucosa o la dermis que comprende buprenorfina y naloxona, util para el tratamiento del dolor.

Country Status (16)

Country Link
US (1) US20110046172A1 (enExample)
EP (1) EP2129380A1 (enExample)
JP (2) JP2010520186A (enExample)
KR (1) KR20090117891A (enExample)
CN (1) CN101626766B (enExample)
AR (1) AR065579A1 (enExample)
AU (1) AU2008220574A1 (enExample)
BR (1) BRPI0807908A2 (enExample)
CA (1) CA2678582A1 (enExample)
CL (1) CL2008000606A1 (enExample)
GB (1) GB2447016A (enExample)
MX (1) MX2009009131A (enExample)
PE (1) PE20090168A1 (enExample)
TW (1) TWI451868B (enExample)
WO (1) WO2008104738A1 (enExample)
ZA (1) ZA200905664B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US20110033542A1 (en) * 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US8663687B2 (en) 2001-10-12 2014-03-04 Monosol Rx, Llc Film compositions for delivery of actives
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
US8475832B2 (en) * 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US9277748B2 (en) * 2010-03-12 2016-03-08 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Agonist/antagonist compositions and methods of use
US8529914B2 (en) * 2010-06-28 2013-09-10 Richard C. Fuisz Bioactive dose having containing a material for modulating pH of a bodily fluid to help or hinder absorption of a bioactive
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
MX352959B (es) * 2011-08-18 2017-12-15 Biodelivery Sciences Int Inc Dispositivos mucoadhesivos resistentes al abuso para el suministro de buprenorfina.
ME02153B (me) 2011-09-19 2015-10-20 Orexo Ab Nove farmaceutske kompozicije, otporne na zloupotrebu, za tretman zavisnosti od opioida
SG10202012743WA (en) * 2011-12-21 2021-01-28 Biodelivery Sciences Int Inc Transmucosal drug delivery devices for use in chronic pain relief
CN103690495B (zh) * 2013-12-19 2015-04-08 贵州景峰注射剂有限公司 注射用盐酸纳洛酮的冷冻干燥方法
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
AU2015228541B2 (en) 2014-03-14 2020-09-03 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
CN122182527A (zh) 2016-05-05 2026-06-12 阿奎斯蒂弗医疗股份有限公司 增强递送的肾上腺素组合物
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
WO2023076281A1 (en) 2021-10-25 2023-05-04 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
JPH1036265A (ja) * 1996-07-19 1998-02-10 Nitto Denko Corp ブプレノルフィン経皮吸収製剤
AR031682A1 (es) * 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
PT1526848E (pt) * 2002-08-09 2007-08-08 Gruenenthal Gmbh Antagonistas dos receptores de opióides em sistemas transdérmicos contendo buprenorfina
US20050191340A1 (en) * 2002-08-09 2005-09-01 Gruenenthal Gmbh Opioid-receptor antagonists in transdermal systems having buprenorphine

Also Published As

Publication number Publication date
CN101626766A (zh) 2010-01-13
KR20090117891A (ko) 2009-11-13
CA2678582A1 (en) 2008-09-04
AR065579A1 (es) 2009-06-17
HK1139871A1 (en) 2010-09-30
US20110046172A1 (en) 2011-02-24
TW200843773A (en) 2008-11-16
ZA200905664B (en) 2010-10-27
TWI451868B (zh) 2014-09-11
WO2008104738A1 (en) 2008-09-04
GB0703968D0 (en) 2007-04-11
AU2008220574A1 (en) 2008-09-04
EP2129380A1 (en) 2009-12-09
CN101626766B (zh) 2013-07-10
JP2014196325A (ja) 2014-10-16
JP2010520186A (ja) 2010-06-10
PE20090168A1 (es) 2009-03-19
MX2009009131A (es) 2009-09-03
BRPI0807908A2 (pt) 2014-06-17
GB2447016A (en) 2008-09-03

Similar Documents

Publication Publication Date Title
CL2008000608A1 (es) Composicion analgesica en forma de dosificacion parenteral unitaria o en una forma de dosificacion unitaria adecuada para una administracion por la mucosa o la dermis que comprende buprenorfina y naltrexona, util para el tratamiento del dolor.
CL2008000607A1 (es) Composicion analgesica en forma de dosificacion parenteral unitaria o en una forma de dosificacion unitaria adecuada para una administracion por la mucosa o la dermis que comprende buprenorfina y nalmefeno, util para el tratamiento del dolor.
CL2008000610A1 (es) Composicion en forma de dosificacion transdermica o transmucosa que comprende una relacion en peso de buprenorfina a naloxona entre 2,1:1 y 8:1, util para el tratamiento del dolor.
CL2011002858A1 (es) Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor.
DE602007007991D1 (de) Kleinvolumige, orale, transmukosale dosierungsformen mit sufentanil zur schmerzbehandlung
CL2014001450A1 (es) Forma de dosis de liberacion controlada solida que comprende un analgesico opioide dispersado en un material de matriz; metodo de preparacion; uso en el tratamiento del dolor.
CL2013001136A1 (es) Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional.
BRPI0917119A2 (pt) composto, composição farmacêutica, métodos para inibir a poli(adp-ribose) polimerase em um paciente, para tratar uma doença, uso de um composto, e, artigo de fabricação.
CL2012000702A1 (es) Uso de un agonista del receptor de acetilcolina nicotinico alfa-7 para el tratamiento de la discinesia asociada a la terapia con agonista de dopamina en la enfermedad de parkinson.
BRPI0814666A2 (pt) composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida
CL2008002999A1 (es) Uso de una composicion farmeceutica que comprende trns-clominefo para preparar un medicamenteo util en el ratamiento de recuccion de los niveles de glucosa en ayunas en un varon.
AR065392A1 (es) Metodos para el tratamiento por inhalacion de una enfermedad o estado respiratorio
CL2012003340A1 (es) Composicion farmaceutica de administracion oral de bendamustina y su uso en el tratamiento oral de una condicion medica seleccionada de leucemia linfocitica cronica, cancer de mama, entre otras.
BRPI0922452A2 (pt) composto, composição farmacêutica, uso em um composto, e método para prevenir, tratar ou melhorar doenças ou condições dérmicas, ou distúrbios de ferimento cutâneo agudos ou crônicos.
ECSP109960A (es) Gel conteniendo pirfenidona
BR112012003280A2 (pt) composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto.
AP2010005384A0 (en) Devices for the administration of drugs and vaccines in the form of injectable needles.
CL2012000313A1 (es) Composición de dosificación de película que comprende una matriz portadora, entre 2-16 mg de buprenorfina, entre 0,5-5 mg de naloxona y un tampón que proporciona un ph local entre 2-4; procedimiento de preparación; uso en el tratamiento de la dependencia de narcóticos en un usuario.
CL2007002875A1 (es) Composicion farmaceutica recubierta por una pelicula que comprende capecitabina y al menos un disgregante, util en el tratamiento del cancer para pacientes que tienen dificultad para tragar las formas de dosificacion solidas orales.
CL2013001564A1 (es) Metodo para tratar sobrepeso u obesidad que comprende administrar naltrexona y bupropion; metodo para incrementar la biodisponibilidad de naltrexona y bupropion en una terapia combinada; uso de naltrexona y bupropion para tratar sobrepeso u obesisdad e incrementar la biodisponibilidad de estos farmacos; composicion farmaceutica.
CL2009001841A1 (es) Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.
CL2008000965A1 (es) Composicion farmaceutica que comprende un agente antiinflamatorio no esteroideo y un analgesico opiaceo, y su uso para el tratamiento del dolor.
BRPI0810773A2 (pt) Composição farmacêutica, métodos para tratar dor em um mamífero, para tratar depressão em um mamífero, para tratar um distúrbio em um paciente, para fabricar um composto, e para inibir a captação de norepinefrina, composto, e, uso de uma composição.
CL2016000170A1 (es) Combinación de oxicodona y naloxona para su uso en el tratamiento del dolor en pacientes que sufren de dolor y una enfermedad que resulta en disbiosis intestinal y/o aumento del riesgo de la translocación bacteriana intestinal.
CL2011000388A1 (es) Combinacion farmaceutica que comprende (6-dimetilaminometil-1-(3-metoxifenil)-ciclohexano-1,3-diol y un antiinflamatorio no esteroidal; forma de dosificacion; uso en el tratamiento de la osteoartritis y el dolor.